The Ambitious Pipeline of EpiCept Corporation
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
The information could allow researchers to observe cellular changes as a patient undergoes cancer treatment, and could aid in the development of new molecular therapeutics for diseases such as cancer.
Copyright © 2024 | WordPress Theme by MH Themes